Acesso livre
Acesso livre

Vacinas

Estudos mostram que a vacinação dos pais forneceu proteção indireta das crianças contra a infecção pelo SARS-CoV-2 durante a onda da variante Delta.

31 Jan, 2022 | 09:03h

Indirect protection of children from SARS-CoV-2 infection through parental vaccination – Science

Ver também: Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel – Science

Comentário: COVID vaccine markedly cuts household transmission, studies show – CIDRAP

 

Comentário no Twitter

 

Análise observacional na Lombardia, na Itália, mostrou uma redução gradual na proteção contra os desfechos clínicos de SARS-CoV-2 após a segunda dose da vacina.

31 Jan, 2022 | 09:02h

Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy – The Lancet Infectious Diseases

Comentário: COVID-19 vaccine: what are we doing and what should we do? – The Lancet Infectious Diseases

Miocardite após vacinação de adolescentes com BNT162b2 em Israel.

31 Jan, 2022 | 08:55h

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents – New England Journal of Medicine

Conteúdos relacionados:

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

Comentário no Twitter

 

Estudo randomizado | Vacinação heteróloga de AD5-nCOV com CoronaVac vs. vacinação homóloga com CoronaVac.

28 Jan, 2022 | 17:20h

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial – Nature Medicine

Conteúdos relacionados:

RCT: Heterologous (Pfizer, J&J, or AstraZeneca) vs. homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil.

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination – Nature Medicine

WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.

Estudo laboratorial italiano mostra que a vacina Sputnik V supera a vacina de mRNA da Pfizer contra a variante Ômicron – produzindo níveis maiores de anticorpos.

28 Jan, 2022 | 16:21h

Italian Lab Study Finds Sputnik V Beat Pfizer’s mRNA Vaccine Against Omicron – Yielding Higher Antibody Levels – Health Policy Watch

Estudo randomizado | Reforço de vacinação heterólogo (Pfizer, J&J ou AstraZeneca) vs. homólogo em pessoas que receberam previamente 2 doses da vacina CoronaVac no Brasil.

28 Jan, 2022 | 15:47h

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study – The Lancet

Comentários:

Boosting immunity after CoronaVac – The Lancet

Covid-19: CoronaVac immunity is strongest after boosting with a different vaccine – The BMJ

Estudo relacionado: Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination – Nature Medicine

 

Comentário no Twitter

 

Casos de miocardite relatados após vacinação contra COVID-19 baseada em mRNA nos EUA de dezembro de 2020 até agosto de 2021.

28 Jan, 2022 | 15:43h

Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 – JAMA

Comentário: COVID 19: Risk of Myocarditis Highest Following Second Vaccine Dose Among Adolescent and Young Adult Males – MedicalResearch.com

Conteúdos relacionados:

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

OMS deixa de se opor aos reforços de vacina – recomenda a terceira dose da Pfizer para adultos e 2 doses de vacinas para crianças a partir de 5 anos de idade.

25 Jan, 2022 | 15:06h

WHO Drops Opposition to Boosters – Recommends Third Pfizer Jab for Adults & Two Vaccines for Children Ages 5 & Up – Health Policy Watch

Conteúdos relacionados:

WHO updated roadmap for prioritizing uses of COVID-19 vaccines.

WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids.

Um estudo de caso-controle mostrou risco aumentado de miocardite após vacinação contra COVID-19 com vacina mRNA em comparação com vacina de vírus inativado.

25 Jan, 2022 | 15:04h

Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine: A Case–Control Study – Annals of Internal Medicine

Comunicado de imprensa: BNT162b2 COVID-19 vaccine associated with increased risk of carditis – American College of Physicians

Conteúdos relacionados:

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

Roteiro atualizado da OMS para priorizar o uso das vacinas contra COVID-19.

25 Jan, 2022 | 12:03h

WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines – World Health Organization

Comentário: WHO: COVID boosters should start with most vulnerable – Associated Press

 

Comentário no Twitter (fio – clique para saber mais)

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.